ZULUTH GEL

Indications

• Osteoarthritis
• Rheumatoid arthritis
• Mild to moderate acute pain
• Dysmenorrhea
• Postoperative pain

Dosage

Children: Refer to the BNF for Children for appropriate dosing information in the paediatric population, as it is essential to adjust doses based on age and weight.

Adults: Refer to the specific BNF or clinical guidelines for adult dosing information, as it can vary based on the condition being treated and patient factors.

Mechanism of action

Cacedofenac exerts its effects by inhibiting the activity of cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. This inhibition leads to a decrease in the synthesis of prostaglandins, which are mediators of inflammation and pain. By reducing the levels of these inflammatory mediators, cacedofenac alleviates symptoms associated with inflammation and pain.

Pharmacodynamics

The pharmacodynamic effects of cacedofenac include its ability to reduce pain and inflammation. The analgesic effect is typically observed within a few hours after administration due to its rapid onset of action. Cacedofenac also has antipyretic properties, which can help in reducing fever. Its efficacy in pain relief and anti-inflammatory action makes it suitable for various musculoskeletal conditions.

Pharmacokinetics

Cacedofenac is absorbed rapidly from the gastrointestinal tract, with peak plasma concentrations usually achieved within 1 to 2 hours following oral administration. It is extensively metabolized in the liver, primarily via conjugation processes. The elimination half-life of cacedofenac is approximately 2 to 4 hours, with metabolites excreted primarily through the urine. The pharmacokinetic profile may vary based on factors such as age and liver function.

Contra-indications

• Hypersensitivity to cacedofenac or any of its excipients
• Active gastrointestinal bleeding or peptic ulcer disease
• Severe hepatic impairment
• History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs
• Severe heart failure

Adverse effects

• Gastrointestinal disturbances (nausea, vomiting, diarrhea, constipation, abdominal pain)
• Dizziness or headache
• Renal impairment
• Hepatotoxicity
• Skin reactions (rash, pruritus)
• Cardiovascular events (hypertension, increased risk of thrombotic events)

Interactions

• Anticoagulants (increased risk of bleeding)
• Other NSAIDs or corticosteroids (increased risk of gastrointestinal toxicity)
• Diuretics (reduced efficacy of diuretics and potential renal impairment)
• ACE inhibitors (potential for renal impairment)
• Lithium (increased lithium levels)

Precautions

• Use with caution in patients with a history of gastrointestinal disease
• Monitor renal function in patients with existing renal impairment
• Caution in patients with cardiovascular disease
• Avoid in patients with dehydration or hypovolemia
• Assess for potential drug interactions prior to initiation

Pregnancy

Cacedofenac should be avoided during pregnancy, particularly in the third trimester, due to potential risks of fetal harm and premature closure of the ductus arteriosus.

Breast-feeding

Cacedofenac is not recommended during breastfeeding, as it is excreted in breast milk and may affect the nursing infant.

Storage

Store at room temperature, away from moisture and heat. Keep out of reach of children.

Formulations

• Tablets
• Oral suspension
• Topical gel

Indications

• Dietary supplement for omega-3 fatty acid intake
• Support for cardiovascular health
• Management of hyperlipidemia
• Support for digestive health
• Potential adjunct in cancer prevention strategies

Dosage

Children: Refer to specific product guidelines and consult a healthcare provider

Adults: Refer to specific product guidelines and consult a healthcare provider for appropriate dosing based on individual health needs.

Mechanism of action

The primary active components of ginseed, particularly alpha-linolenic acid, exert their effects by modulating inflammatory pathways and promoting the production of anti-inflammatory cytokines. Furthermore, lignans in ginseed are thought to exhibit estrogenic activity and may help in the modulation of hormonal balance. The fiber content contributes to improved gastrointestinal health and aids in cholesterol management by binding bile acids and reducing their reabsorption.

Pharmacodynamics

Ginseed exhibits several pharmacodynamic effects, primarily through its omega-3 fatty acids which can lower triglyceride levels, reduce blood pressure, and improve endothelial function. The soluble fiber in ginseed enhances satiety, aids in blood glucose control, and promotes regular bowel movements. Lignans may provide additional health benefits, including potential cancer-protective effects due to their antioxidant properties.

Pharmacokinetics

The pharmacokinetics of ginseed components can vary based on the form of consumption. ALA is absorbed in the small intestine and is then transported via chylomicrons into the bloodstream. The conversion of ALA to longer-chain omega-3 fatty acids (EPA and DHA) occurs but is limited. Fiber components are not digested and reach the colon, where they can be fermented by gut bacteria. The bioavailability of lignans is also influenced by gut microbiota, which can convert them into enterolignans that are then absorbed.

Pregnancy

There is insufficient data regarding the safety of ginseed during pregnancy. It is advisable to avoid use unless prescribed by a qualified healthcare provider.

Breast-feeding

Due to limited information on the excretion of ginseed in breast milk, it is recommended to consult a healthcare professional before use while breastfeeding.

Storage

Store in a cool, dry place, away from direct sunlight and moisture. Ensure the container is tightly sealed.

Indications

• Topical analgesic for muscle and joint pain
• Cough suppressant in cough drops and lozenges
• Relief of minor throat irritation
• Cooling agent in various cosmetic and personal care products

Dosage

Children: Refer to BNF for Children for specific dosing guidelines, as doses may vary based on age and formulation.

Adults: For topical use, apply a thin layer to the affected area not more than 3 to 4 times daily. For cough drops, follow the product-specific instructions as per the formulation.

Mechanism of action

Menthol acts as an agonist for the transient receptor potential subtype M8 (TRPM8), a non-selective cation channel that is activated by cold temperatures. This activation leads to calcium influx in mast cells, inducing the release of histamine, which can trigger allergic responses such as urticaria, asthma, and rhinitis. Menthol's ability to induce histamine release via TRPM8 suggests potential therapeutic applications for TRPM8 antagonists in managing cold- and menthol-induced allergies.

Pharmacodynamics

Menthol produces a cooling effect by stimulating sensory neurons that convey cold sensations. It interacts with TRPM8 channels, leading to the activation of intracellular signaling pathways that can result in vasodilation and increased blood flow to the area of application. This cooling sensation can provide symptomatic relief in conditions characterized by pain or irritation.

Pharmacokinetics

Menthol is absorbed through the skin and mucous membranes, with systemic effects depending on the route of administration. Its bioavailability can vary, and it is metabolized primarily in the liver. The elimination half-life and excretion pathways have not been extensively characterized, but menthol is generally considered to have a rapid onset of action with effects lasting for a few hours.

Adverse effects

• Allergic reactions
• Urticaria
• Asthma
• Rhinitis
• Skin irritation

Precautions

• Use with caution in patients with known allergies to menthol or related compounds
• May exacerbate asthma in sensitive individuals

Pregnancy

There are no well-controlled studies of menthol in pregnant women. Menthol should be used during pregnancy only if clearly needed.

Breast-feeding

Menthol is excreted in breast milk. Caution should be exercised when administering to nursing mothers.

Storage

Store in a cool, dry place away from light. Keep out of reach of children.

Formulations

• Topical ointment
• Cream
• Liquid

Indications

• Allergic conditions
• Autoimmune diseases
• Asthma and chronic obstructive pulmonary disease (COPD)
• Certain cancers (e.g., leukemia, lymphoma)
• Skin conditions (e.g., dermatitis)
• Inflammatory bowel disease
• Multiple sclerosis exacerbations
• Severe infections requiring immunosuppression

Dosage

Children: Refer to BNF for Children for specific dosing; doses vary significantly based on the child's age, weight, and condition being treated.

Adults: Refer to BNF for specific dosing; typically, initial doses range from 4 to 48 mg depending on the severity of the condition.

Mechanism of action

Methylprednisolone exerts its effects by binding to glucocorticoid receptors, leading to the modulation of gene expression. This interaction influences the transcription of anti-inflammatory proteins while suppressing the expression of pro-inflammatory genes, ultimately resulting in reduced inflammation and immune response.

Pharmacodynamics

The pharmacodynamic effects of methylprednisolone are characterized by its ability to decrease inflammation, suppress the immune response, and affect carbohydrate metabolism. Therapeutic doses lead to various systemic effects, including modification of leukocyte distribution and inhibition of cytokine production.

Pharmacokinetics

Methylprednisolone is well absorbed after oral administration, with a bioavailability of approximately 50%. It has a volume of distribution that reflects extensive tissue binding. The drug is metabolized primarily in the liver through conjugation and reduction, and its metabolites are excreted in urine. The half-life varies based on the route of administration but is generally around 18 to 36 hours.

Adverse effects

• Increased blood pressure
• Hyperglycemia
• Weight gain
• Mood changes
• Insomnia
• Gastrointestinal disturbances
• Increased susceptibility to infections

Interactions

• methylphenidate+apraclonidine: Severe (decreases effects)
• methylthioninium chloride+bupropion: Severe (increases risk of severe hypertension)
• methylphenidate+linezolid: Severe (increases risk of elevated blood pressure)
• rasagiline+methylphenidate: Severe (increases risk of a hypertensive crisis)
• mao-inhibitors+methylphenidate: Severe (increases risk of a hypertensive crisis)
• dronedarone+methylprednisolone: Moderate (increases exposure)
• miconazole+methylprednisolone: Moderate (increases concentration)
• antifungals, azoles+methylprednisolone: Moderate (increases exposure)
• crizotinib+methylprednisolone: Moderate (increases exposure)

Precautions

• Use with caution in patients with hypertension
• Monitor blood glucose levels in diabetic patients
• Consider potential for infection risk due to immunosuppression
• Evaluate for psychiatric effects in susceptible individuals

Pregnancy

Corticosteroids may be used during pregnancy if the potential benefit justifies the risk to the fetus. Careful monitoring is advised.

Breast-feeding

Corticosteroids are excreted in breast milk; caution is advised. Monitor the infant for potential effects.

Storage

Store in a cool, dry place, away from light. Keep out of reach of children.

Formulations

• Tablets
• Injectable solutions
• Topical preparations

Mechanism of action

Methylsulphate functions as a methylating agent, transferring a methyl group to nucleophiles. This process involves the formation of a sulfonium ion, which is highly reactive and can readily react with nucleophilic sites on various substrates, leading to methylation reactions.

Pharmacodynamics

The pharmacodynamics of methylsulphate is primarily related to its role as a methylating agent in biochemical reactions. It can alter the structure and function of biological molecules, potentially affecting cellular processes and signaling pathways. However, detailed pharmacodynamic studies specific to therapeutic use are limited.

Pharmacokinetics

There is limited information on the pharmacokinetics of methylsulphate, given its typical use as a reagent in laboratory settings rather than a clinical drug. When used in chemical reactions, its reactivity and transformation into other compounds would dictate its pharmacokinetic profile, which could vary significantly based on the specific context of use.

Pregnancy

There is limited data on the use of methylsulphate in pregnancy. Consult relevant guidelines.

Breast-feeding

Data on the excretion of methylsulphate in human milk is not available. Caution is advised.

Storage

Store in a cool, dry place, away from direct sunlight.

Indications

• Hypertension
• Peripheral vascular disease
• Raynaud's phenomenon
• Angina pectoris

Dosage

Children: Refer to pediatric dosing guidelines or clinical references, as specific dosing has not been established.

Adults: Refer to prescribing information or clinical guidelines for exact dosing, as it may vary based on specific clinical circumstances.

Mechanism of action

Thiodolchcosid acts as a vasodilator by inhibiting calcium ion influx in vascular smooth muscle, leading to relaxation of the muscle and subsequent dilation of blood vessels. This results in decreased peripheral resistance and lowered blood pressure. Additionally, it may act on the nitric oxide signaling pathway, promoting vasodilation through increased cGMP levels.

Pharmacodynamics

The pharmacodynamics of thiodolchcosid involve its ability to reduce systemic vascular resistance, thereby lowering blood pressure. It can also improve oxygen delivery to tissues by increasing blood flow, which is particularly beneficial in conditions where ischemia is present. The onset of action is typically within a few hours, with peak effects occurring later.

Pharmacokinetics

Thiodolchcosid is well-absorbed after oral administration, with peak plasma concentrations achieved within a few hours. It undergoes hepatic metabolism, and its elimination half-life is variable, often ranging from several hours to a day. The drug is primarily excreted in urine as metabolites, with a small percentage eliminated unchanged.

Pregnancy

There is limited data on the use of thiodolchcosid during pregnancy. It should only be used if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether thiodolchcosid is excreted in human milk. Caution should be exercised when administering to breastfeeding women.

Storage

Store at room temperature, away from moisture and heat. Keep out of reach of children.

Mechanism of action

Exposure to low temperatures often causes allergic responses or urticaria. Similarly, menthol, a common food additive is also known to cause urticaria, asthma, and rhinitis. However, despite the obvious clinical implications, the molecular mechanisms responsible for inducing allergic responses to low temperatures and menthol have not been determined. Because a non-selective cation channel, transient receptor potential subtype M8 (TRPM8) is activated by cold and menthol, we hypothesized that this channel mediates cold- and menthol-induced histamine release in mast cells. Here, we report that TRPM8 is expressed in the basophilic leukemia mast cell line, RBL-2H3, and that exposure to menthol or low temperatures induced Ca(2+) influx in RBL-2H3 cells, which was reversed by a TRPM8 blocker. Furthermore, menthol, a TRPM8 agonist, induced the dose-dependent release of histamine from RBL-2H3 cells. When TRPM8 transcripts were reduced by siRNA (small interfering RNA), menthol- and cold-induced Ca(2+) influx and histamine release were significantly reduced. In addition, subcutaneous injection of menthol evoked scratching, a typical histamine-induced response which was reversed by a TRPM8 blocker. Thus, our findings indicate that TRPM8 mediates the menthol- and cold-induced allergic responses of mast cells, and suggest that TRPM8 antagonists be viewed as potential treatments for cold- and menthol-induced allergies. /DL-Menthol/ Menthol's characteristic cooling sensation is due, in part, to the activation of sensory neurons generally termed transient receptor potential (TRP) channels, in particular transient receptor potential melastatin family member 8 (TRPM8) and transient receptor potential subfamily A, member 1 (TRPA1). Menthol acts upon TRPM8 receptors by rapidly increasing intracellular calcium and mobilizing calcium flux through the channels to induce cold response signals at the application site. Aside from its cold-inducing sensation capabilities, menthol exhibits cytotoxic effects in cancer cells, induces reduction in malignant cell growth, and engages in synergistic excitation of GABA receptors and sodium ion channels resulting in analgesia. /DL-Menthol/ In recent years, the transient receptor potential melastatin member 8 (TRPM8) channel has emerged as a promising prognostic marker and putative therapeutic target in prostate cancer. We have found that forced overexpression of TRPM8 in PC-3 cells can inhibit the cell proliferation and motility probably through the TRPM8 activation. In this study, we aimed to investigate whether activating the TRPM8 channel by its selective agonist menthol can inhibit the proliferation and motility of androgen-independent prostate cancer (AIPC) with remarkable expression of TRPM8. Menthol is a naturally occurring compound, which has been widely used in cosmetics and pharmaceutical products, and also as flavoring in food. DU145 cells are androgen-independent but have a remarkable expression of TRPM8. The demonstration of the existence of TRPM8 and the absence of TRPA1 in DU145 cells provided the foundation for the following experiments, because both TRPM8 and TRPA1 are molecular targets of menthol. The outcome of MTT assay indicated that menthol inhibited the cell growth (p < 0.01). Cell cycle distribution and scratch assay analysis revealed that menthol induced cell cycle arrest at the G(0)/G(1) phase (p < 0.01). Furthermore, menthol inhibited the migration of DU145 cells by downregulating the focal-adhesion kinase. So it suggests that the activation of the existing TRPM8 channels may serve as a potential and pragmatic treatment for those AIPC with remarkable expression of TRPM8, and menthol is a useful compound for future development as an anticancer agent. /DL-Menthol/